The management of chronic myeloid leukemia remains a significant challenge despite the introduction of effective tyrosine kinase inhibitors. At the 20th Congress of the European Hematology Association (EHA), Stephen O’Brien, BSc (Hons), PhD, MBChB, FRCP, FRCPath, of the University of Newcastle, Newcastle upon Tyne, UK, explains possible new strategies that may improve the outlook for these patients.